<?xml version="1.0" encoding="UTF-8"?>
<mx:collection xmlns:mx="http://www.loc.gov/MARC21/slim">
    <mx:record>
        <mx:leader/>
 
        <datafield tag="022" ind1="" ind2="">
            <subfield code="a">1538-4101</subfield>
        </datafield>
        <datafield tag="050" ind1="0" ind2="0">
            <subfield code="a">2002212522</subfield>
        </datafield>
        <datafield tag="060" ind1="0" ind2="0">
            <subfield code="a">101137841</subfield>
        </datafield>
        <datafield tag="130" ind1="" ind2="">
            <subfield code="a">Cell Cycle</subfield>
        </datafield>
        <datafield tag="210" ind1="0" ind2="">
            <subfield code="a">cc</subfield>
        </datafield>
        <datafield tag="260" ind1="3" ind2="">
            <subfield code="a">Austin, Tx</subfield>
            <subfield code="b">Landes Bioscience</subfield>
        </datafield>
        <datafield tag="310" ind1="" ind2="">
            <subfield code="a">biweekly</subfield>
        </datafield>
        <datafield tag="362" ind1="0" ind2="">
            <subfield code="a">January 2002 - </subfield>
        </datafield>
        <datafield tag="856" ind1="4" ind2="">
            
            <subfield code="u">http://dx.doi.org/10.4161/cc</subfield>
            <subfield code="u">http://www.landesbioscience.com/journals/cc/</subfield>
        </datafield>
    </mx:record>
    <mx:record id="21277">
        <mx:leader/>
        <datafield tag="022" ind1="" ind2="">
            <subfield code="a">1538-4101</subfield>
        </datafield>
        <datafield tag="100" ind1="" ind2="">
            <subfield code="a">Owen M. Siggs and Bruce Beutler</subfield>
        </datafield>
        
        <datafield tag="210" ind1="" ind2="">
            <subfield code="a">cc</subfield>
        </datafield>
        
        <datafield tag="245" ind1="" ind2="">
            <subfield code="a">The BTB-ZF transcription factors</subfield> 
        </datafield>
        
        <datafield tag="260" ind1="3" ind2="">
            <subfield code="b">Landes Bioscience</subfield>
            <subfield code="c">2012-09-15</subfield>
        </datafield>
        
        <datafield tag="302" ind1="" ind2="">
            <subfield code="a">3358 - 3369</subfield>
        </datafield>
        
        <datafield tag="440" ind1="" ind2="">
            
            <subfield code="a">Cell Cycle</subfield>
            <subfield code="v">11-18</subfield>
        </datafield>
        <datafield tag="449" ind1="" ind2="">
            <subfield code="o">Landes Bioscience</subfield>
        </datafield>
        <datafield tag="520" ind1="3" ind2="">
            <subfield code="a">The BTB-ZF (broad-complex, tramtrack and bric-à-brac - zinc finger) proteins are encoded by at least 49 genes in mouse and man and commonly serve as sequence-specific silencers of gene expression. This review will focus on the known physiological functions of mammalian BTB-ZF proteins, which include essential roles in the development of the immune system. We discuss their function in terminally differentiated lymphocytes and the progenitors that give rise to them, their action in hematopoietic malignancy and roles beyond the immune system.</subfield>
        </datafield>
        <datafield tag="856" ind1="4" ind2="">
            
            <subfield code="u">http://dx.doi.org/10.4161/cc.21277</subfield>
            <subfield code="u">http://www.landesbioscience.com/journals/cc/article/21277/</subfield>
        </datafield>
 
        <datafield tag="949" ind1="" ind2="">
            <subfield code="t">article</subfield>
            <subfield code="n">Extra Views</subfield>
        </datafield>
    </mx:record>
    <mx:record id="21290">
        <mx:leader/>
        <datafield tag="022" ind1="" ind2="">
            <subfield code="a">1538-4101</subfield>
        </datafield>
        <datafield tag="100" ind1="" ind2="">
            <subfield code="a">Ming Wang</subfield>
            <subfield code="a">Marianna Halasi</subfield>
            <subfield code="a">Kasim Kabirov</subfield>
            <subfield code="a">Aryamitra Banerjee</subfield>
            <subfield code="a">Jennifer Landolfi</subfield>
            <subfield code="a">Alexander V. Lyubimov and Andrei L. Gartel</subfield>
        </datafield>
        
        <datafield tag="210" ind1="" ind2="">
            <subfield code="a">cc</subfield>
        </datafield>
        
        <datafield tag="245" ind1="" ind2="">
            <subfield code="a">Combination treatment with bortezomib and thiostrepton is effective against tumor formation in mouse models of DEN/PB-induced liver carcinogenesis</subfield> 
        </datafield>
        
        <datafield tag="260" ind1="3" ind2="">
            <subfield code="b">Landes Bioscience</subfield>
            <subfield code="c">2012-09-15</subfield>
        </datafield>
        
        <datafield tag="302" ind1="" ind2="">
            <subfield code="a">3370 - 3372</subfield>
        </datafield>
        
        <datafield tag="440" ind1="" ind2="">
            
            <subfield code="a">Cell Cycle</subfield>
            <subfield code="v">11-18</subfield>
        </datafield>
        <datafield tag="449" ind1="" ind2="">
            <subfield code="o">Landes Bioscience</subfield>
        </datafield>
        <datafield tag="520" ind1="3" ind2="">
            <subfield code="a">Nanoparticle-encapsulated thiazole antibiotic, thiostrepton, has been shown to be an effective agent for inhibiting tumor growth in solid tumor models through the inhibition of proteasomal activity by the induction of apoptosis in cancer cells. Here, we show the efficacy of thiostrepton-micelles in inhibiting tumor growth in a DEN/PB-induced liver cancer model. We also demonstrate an enhanced anticancer effect of the combination treatment of thiostrepton with bortezomib, another proteasome inhibitor in this liver cancer model.</subfield>
        </datafield>
        <datafield tag="856" ind1="4" ind2="">
            
            <subfield code="u">http://dx.doi.org/10.4161/cc.21290</subfield>
            <subfield code="u">http://www.landesbioscience.com/journals/cc/article/21290/</subfield>
        </datafield>
 
        <datafield tag="949" ind1="" ind2="">
            <subfield code="t">article</subfield>
            <subfield code="n">Extra Views</subfield>
        </datafield>
    </mx:record>
    <mx:record id="21397">
        <mx:leader/>
        <datafield tag="022" ind1="" ind2="">
            <subfield code="a">1538-4101</subfield>
        </datafield>
        <datafield tag="100" ind1="" ind2="">
            <subfield code="a">Makiko Fujii</subfield>
            <subfield code="a">Hayao Nakanishi</subfield>
            <subfield code="a">Takeshi Toyoda</subfield>
            <subfield code="a">Ichidai Tanaka</subfield>
            <subfield code="a">Yutaka Kondo</subfield>
            <subfield code="a">Hirotaka Osada and Yoshitaka Sekido</subfield>
        </datafield>
        
        <datafield tag="210" ind1="" ind2="">
            <subfield code="a">cc</subfield>
        </datafield>
        
        <datafield tag="245" ind1="" ind2="">
            <subfield code="a">Convergent signaling in the regulation of connective tissue growth factor in malignant mesothelioma: TGFβ signaling and defects in the Hippo signaling cascade</subfield> 
        </datafield>
        
        <datafield tag="260" ind1="3" ind2="">
            <subfield code="b">Landes Bioscience</subfield>
            <subfield code="c">2012-09-15</subfield>
        </datafield>
        
        <datafield tag="302" ind1="" ind2="">
            <subfield code="a">3373 - 3379</subfield>
        </datafield>
        
        <datafield tag="440" ind1="" ind2="">
            
            <subfield code="a">Cell Cycle</subfield>
            <subfield code="v">11-18</subfield>
        </datafield>
        <datafield tag="449" ind1="" ind2="">
            <subfield code="o">Landes Bioscience</subfield>
        </datafield>
        <datafield tag="520" ind1="3" ind2="">
            <subfield code="a">Malignant mesothelioma (MM) is a neoplasm that arises from serosal surfaces of the pleural, peritoneal and pericardial cavities with worldwide incidence, much of which is caused by asbestos exposure. Patients suffer from pain and dyspnea due to direct invasion of the chest wall, lungs and vertebral or intercostal nerves by masses of thick fibrotic tumors. Although there has been recent progress in the clinical treatment, current therapeutic approaches do not provide satisfactory results. Therefore, development of a molecularly targeted therapy for MM is urgently required. Our recent studies suggest that normal mesothelial and MM cell growth is promoted by TGFβ, and that TGFβ signaling together with intrinsic disturbances in neurofibromatosis type 2 (NF2) and Hippo signaling cascades in MM cells converges upon further expression of connective tissue growth factor (CTGF). The formation of a YAP-TEAD4–Smad3-p300 complex on the specific CTGF promoter site with an adjacent TEAD and Smad binding motif is a critical and synergistic event caused by the dysregulation of these two distinct cascades. Furthermore, we demonstrated the functional importance of CTGF through the mouse studies and human histological analyses, which may elucidate the clinical features of MM with severe fibrosis in the thoracic cavity.</subfield>
        </datafield>
        <datafield tag="856" ind1="4" ind2="">
            
            <subfield code="u">http://dx.doi.org/10.4161/cc.21397</subfield>
            <subfield code="u">http://www.landesbioscience.com/journals/cc/article/21397/</subfield>
        </datafield>
 
        <datafield tag="949" ind1="" ind2="">
            <subfield code="t">article</subfield>
            <subfield code="n">Extra Views</subfield>
        </datafield>
    </mx:record>
    <mx:record id="21401">
        <mx:leader/>
        <datafield tag="022" ind1="" ind2="">
            <subfield code="a">1538-4101</subfield>
        </datafield>
        <datafield tag="100" ind1="" ind2="">
            <subfield code="a">Olivier Elemento</subfield>
            <subfield code="a">Mark A. Rubin and David S. Rickman</subfield>
        </datafield>
        
        <datafield tag="210" ind1="" ind2="">
            <subfield code="a">cc</subfield>
        </datafield>
        
        <datafield tag="245" ind1="" ind2="">
            <subfield code="a">Oncogenic transcription factors as master regulators of chromatin topology: A new role for ERG in prostate cancer</subfield> 
        </datafield>
        
        <datafield tag="260" ind1="3" ind2="">
            <subfield code="b">Landes Bioscience</subfield>
            <subfield code="c">2012-09-15</subfield>
        </datafield>
        
        <datafield tag="302" ind1="" ind2="">
            <subfield code="a">3380 - 3383</subfield>
        </datafield>
        
        <datafield tag="440" ind1="" ind2="">
            
            <subfield code="a">Cell Cycle</subfield>
            <subfield code="v">11-18</subfield>
        </datafield>
        <datafield tag="449" ind1="" ind2="">
            <subfield code="o">Landes Bioscience</subfield>
        </datafield>
        <datafield tag="520" ind1="3" ind2="">
            <subfield code="a">The three-dimensional (3D) conformation of the genome is known to be structured and to affect gene transcription, but how chromatin conformation changes in diseases such as cancer is poorly understood. Similarly, oncogenic transcription factors bind to thousands of sites in the genome without a clear transcriptional role on nearby genes. Could these factors play a non-transcriptional role in promoting tumor progression by restructuring the shape of the genome? To address this question, we recently performed unbiased high-resolution mapping of intra- and inter-chromosome interactions upon overexpression of ERG, an oncogenic transcription factor frequently overexpressed in prostate cancer as a result of a gene fusion. By integrating data from genome-wide chromosome conformation capture (Hi-C), ERG binding and gene expression, we have demonstrated that oncogenic transcription factor overexpression is associated with global, reproducible and functionally coherent changes in chromatin organization. Perhaps more importantly, we have identified novel genomic alterations associated with ERG overexpression. These results suggest a yet unappreciated role for transcription factors in promoting genomic alterations through their effect on chromatin architecture.</subfield>
        </datafield>
        <datafield tag="856" ind1="4" ind2="">
            
            <subfield code="u">http://dx.doi.org/10.4161/cc.21401</subfield>
            <subfield code="u">http://www.landesbioscience.com/journals/cc/article/21401/</subfield>
        </datafield>
 
        <datafield tag="949" ind1="" ind2="">
            <subfield code="t">article</subfield>
            <subfield code="n">Extra Views</subfield>
        </datafield>
    </mx:record>
    <mx:record id="21404">
        <mx:leader/>
        <datafield tag="022" ind1="" ind2="">
            <subfield code="a">1538-4101</subfield>
        </datafield>
        <datafield tag="100" ind1="" ind2="">
            <subfield code="a">Walter Becker</subfield>
        </datafield>
        
        <datafield tag="210" ind1="" ind2="">
            <subfield code="a">cc</subfield>
        </datafield>
        
        <datafield tag="245" ind1="" ind2="">
            <subfield code="a">Emerging role of DYRK family protein kinases as regulators of protein stability in cell cycle control</subfield> 
        </datafield>
        
        <datafield tag="260" ind1="3" ind2="">
            <subfield code="b">Landes Bioscience</subfield>
            <subfield code="c">2012-09-15</subfield>
        </datafield>
        
        <datafield tag="302" ind1="" ind2="">
            <subfield code="a">3389 - 3394</subfield>
        </datafield>
        
        <datafield tag="440" ind1="" ind2="">
            
            <subfield code="a">Cell Cycle</subfield>
            <subfield code="v">11-18</subfield>
        </datafield>
        <datafield tag="449" ind1="" ind2="">
            <subfield code="o">Landes Bioscience</subfield>
        </datafield>
        <datafield tag="520" ind1="3" ind2="">
            <subfield code="a">Dual-specificity tyrosine phosphorylation-regulated kinases (DYRKs) constitute an evolutionarily conserved family of protein kinases with key roles in the control of cell proliferation and differentiation. Members of the DYRK family phosphorylate many substrates, including critical regulators of the cell cycle. A recent report revealed that human DYRK2 acts as a negative regulator of G&lt;sub&gt;1&lt;/sub&gt;/S transition by phosphorylating c-Jun and c-Myc, thereby inducing ubiquitination-mediated degradation. Other DYRKs also function as cell cycle regulators by modulating the turnover of their target proteins. DYRK1B can induce reversible cell arrest in a quiescent G&lt;sub&gt;0&lt;/sub&gt; state by targeting cyclin D1 for proteasomal degradation and stabilizing p27&lt;sup&gt;Kip1&lt;/sup&gt;. The DYRK2 ortholog of &lt;em&gt;C. elegans&lt;/em&gt;, MBK-2, triggers the proteasomal destruction of oocyte proteins after meiosis to allow the mitotic divisions in embryo development. This review summarizes the accumulating results that provide evidence for a general role of DYRKs in the regulation of protein stability.</subfield>
        </datafield>
        <datafield tag="856" ind1="4" ind2="">
            
            <subfield code="u">http://dx.doi.org/10.4161/cc.21404</subfield>
            <subfield code="u">http://www.landesbioscience.com/journals/cc/article/21404/</subfield>
        </datafield>
 
        <datafield tag="949" ind1="" ind2="">
            <subfield code="t">article</subfield>
            <subfield code="n">Perspective</subfield>
        </datafield>
    </mx:record>
    <mx:record id="21461">
        <mx:leader/>
        <datafield tag="022" ind1="" ind2="">
            <subfield code="a">1538-4101</subfield>
        </datafield>
        <datafield tag="100" ind1="" ind2="">
            <subfield code="a">Yan Gonghong</subfield>
            <subfield code="a">Yumei Lai and Yu Jiang</subfield>
        </datafield>
        
        <datafield tag="210" ind1="" ind2="">
            <subfield code="a">cc</subfield>
        </datafield>
        
        <datafield tag="245" ind1="" ind2="">
            <subfield code="a">TOR under stress: Targeting TORC1 by Rho1 GTPase</subfield> 
        </datafield>
        
        <datafield tag="260" ind1="3" ind2="">
            <subfield code="b">Landes Bioscience</subfield>
            <subfield code="c">2012-09-15</subfield>
        </datafield>
        
        <datafield tag="302" ind1="" ind2="">
            <subfield code="a">3384 - 3388</subfield>
        </datafield>
        
        <datafield tag="440" ind1="" ind2="">
            
            <subfield code="a">Cell Cycle</subfield>
            <subfield code="v">11-18</subfield>
        </datafield>
        <datafield tag="449" ind1="" ind2="">
            <subfield code="o">Landes Bioscience</subfield>
        </datafield>
        <datafield tag="520" ind1="3" ind2="">
            <subfield code="a">In the yeast &lt;em&gt;Saccharomyces cerevisiae,&lt;/em&gt; small GTPase Rho1 controls polarized actin distribution and cell wall expansion in response to many different environmental and intracellular stimuli. Its activity is essential for cell survival and adaptation under various stress conditions. A recent study identified the TOR complex 1 (TORC1), a central regulator in cell growth and metabolism, as a direct target of the small GTPase. This novel crosstalk extends the signaling network of Rho1 into many TORC1-dependent processes and sheds light on how yeast cells coordinate polarized spatial expansion with mass increase.</subfield>
        </datafield>
        <datafield tag="856" ind1="4" ind2="">
            
            <subfield code="u">http://dx.doi.org/10.4161/cc.21461</subfield>
            <subfield code="u">http://www.landesbioscience.com/journals/cc/article/21461/</subfield>
        </datafield>
 
        <datafield tag="949" ind1="" ind2="">
            <subfield code="t">article</subfield>
            <subfield code="n">Extra Views</subfield>
        </datafield>
    </mx:record>
    <mx:record id="21848">
        <mx:leader/>
        <datafield tag="022" ind1="" ind2="">
            <subfield code="a">1538-4101</subfield>
        </datafield>
        <datafield tag="100" ind1="" ind2="">
            <subfield code="a">Edward M. Johnson</subfield>
        </datafield>
        
        <datafield tag="210" ind1="" ind2="">
            <subfield code="a">cc</subfield>
        </datafield>
        
        <datafield tag="245" ind1="" ind2="">
            <subfield code="a">The fox and the fat: An unexpected new treatment for brain tumors</subfield> 
        </datafield>
        
        <datafield tag="260" ind1="3" ind2="">
            <subfield code="b">Landes Bioscience</subfield>
            <subfield code="c">2012-09-15</subfield>
        </datafield>
        
        <datafield tag="302" ind1="" ind2="">
            <subfield code="a">3353 - 3353</subfield>
        </datafield>
        
        <datafield tag="440" ind1="" ind2="">
            
            <subfield code="a">Cell Cycle</subfield>
            <subfield code="v">11-18</subfield>
        </datafield>
        <datafield tag="449" ind1="" ind2="">
            <subfield code="o">Landes Bioscience</subfield>
        </datafield>
        <datafield tag="520" ind1="3" ind2="">
            <subfield code="a">Comment on: Wilk A, et al. Cell Cycle 2012; 11:2660-71.</subfield>
        </datafield>
        <datafield tag="856" ind1="4" ind2="">
            
            <subfield code="u">http://dx.doi.org/10.4161/cc.21848</subfield>
            <subfield code="u">http://www.landesbioscience.com/journals/cc/article/21848/</subfield>
        </datafield>
 
        <datafield tag="949" ind1="" ind2="">
            <subfield code="t">article</subfield>
            <subfield code="n">Cell Cycle News &amp; Views</subfield>
        </datafield>
    </mx:record>
    <mx:record id="21694">
        <mx:leader/>
        <datafield tag="022" ind1="" ind2="">
            <subfield code="a">1538-4101</subfield>
        </datafield>
        <datafield tag="100" ind1="" ind2="">
            <subfield code="a">Yuka Machida</subfield>
            <subfield code="a">Myoung Shin Kim and Yuichi J. Machida</subfield>
        </datafield>
        
        <datafield tag="210" ind1="" ind2="">
            <subfield code="a">cc</subfield>
        </datafield>
        
        <datafield tag="245" ind1="" ind2="">
            <subfield code="a">Spartan/C1orf124 is important to prevent UV-induced mutagenesis</subfield> 
        </datafield>
        
        <datafield tag="260" ind1="3" ind2="">
            <subfield code="b">Landes Bioscience</subfield>
            <subfield code="c">2012-09-15</subfield>
        </datafield>
        
        <datafield tag="302" ind1="" ind2="">
            <subfield code="a">3395 - 3402</subfield>
        </datafield>
        
        <datafield tag="440" ind1="" ind2="">
            
            <subfield code="a">Cell Cycle</subfield>
            <subfield code="v">11-18</subfield>
        </datafield>
        <datafield tag="449" ind1="" ind2="">
            <subfield code="o">Landes Bioscience</subfield>
        </datafield>
        <datafield tag="520" ind1="3" ind2="">
            <subfield code="a">Uninterrupted replication across damaged DNA is critical to prevent replication fork collapse and resulting double-strand DNA breaks. Rad18-mediated PCNA ubiquitination is a crucial event that triggers a number of downstream pathways important for lesion bypass. Here, we report characterization of Spartan, an evolutionarily conserved protein containing a PCNA-interacting peptide motif, called a PIP box, and a UBZ4 ubiquitin-binding domain. Spartan is a nuclear protein and forms DNA damage-induced foci that colocalize with markers for stalled DNA replication. Focus formation of Spartan requires its PIP-box and the UBZ4 domain and is dependent on Rad18 and the PCNA ubiquitination site, indicating that Spartan is recruited to ubiquitinated PCNA. Spartan depletion results in increased mutagenesis during replication of UV-damaged DNA. Taken together, our data suggest that Spartan is recruited to sites of stalled replication via ubiquitinated PCNA and plays an important role to prevent mutations associated with replication of damaged DNA.</subfield>
        </datafield>
        <datafield tag="856" ind1="4" ind2="">
            
            <subfield code="u">http://dx.doi.org/10.4161/cc.21694</subfield>
            <subfield code="u">http://www.landesbioscience.com/journals/cc/article/21694/</subfield>
        </datafield>
 
        <datafield tag="949" ind1="" ind2="">
            <subfield code="t">article</subfield>
            <subfield code="n">Report</subfield>
        </datafield>
    </mx:record>
    <mx:record id="21701">
        <mx:leader/>
        <datafield tag="022" ind1="" ind2="">
            <subfield code="a">1538-4101</subfield>
        </datafield>
        <datafield tag="100" ind1="" ind2="">
            <subfield code="a">Valentina Carito</subfield>
            <subfield code="a">Gloria Bonuccelli</subfield>
            <subfield code="a">Ubaldo E. Martinez-Outschoorn</subfield>
            <subfield code="a">Diana Whitaker-Menezes</subfield>
            <subfield code="a">Maria Cristina Caroleo</subfield>
            <subfield code="a">Erika Cione</subfield>
            <subfield code="a">Anthony Howell</subfield>
            <subfield code="a">Richard G. Pestell</subfield>
            <subfield code="a">Michael P. Lisanti and Federica Sotgia</subfield>
        </datafield>
        
        <datafield tag="210" ind1="" ind2="">
            <subfield code="a">cc</subfield>
        </datafield>
        
        <datafield tag="245" ind1="" ind2="">
            <subfield code="a">Metabolic remodeling of the tumor microenvironment: Migration stimulating factor (MSF) reprograms myofibroblasts toward lactate production, fueling anabolic tumor growth</subfield> 
        </datafield>
        
        <datafield tag="260" ind1="3" ind2="">
            <subfield code="b">Landes Bioscience</subfield>
            <subfield code="c">2012-09-15</subfield>
        </datafield>
        
        <datafield tag="302" ind1="" ind2="">
            <subfield code="a">3403 - 3414</subfield>
        </datafield>
        
        <datafield tag="440" ind1="" ind2="">
            
            <subfield code="a">Cell Cycle</subfield>
            <subfield code="v">11-18</subfield>
        </datafield>
        <datafield tag="449" ind1="" ind2="">
            <subfield code="o">Landes Bioscience</subfield>
        </datafield>
        <datafield tag="520" ind1="3" ind2="">
            <subfield code="a">Migration stimulating factor (MSF) is a genetically truncated N-terminal isoform of fibronectin that is highly expressed during mammalian development in fetal fibroblasts, and during tumor formation in human cancer-associated myofibroblasts. However, its potential functional role in regulating tumor metabolism remains unexplored. Here, we generated an immortalized fibroblast cell line that recombinantly overexpresses MSF and studied their properties relative to vector-alone control fibroblasts. Our results indicate that overexpression of MSF is sufficient to confer myofibroblastic differentiation, likely via increased TGF-b signaling. In addition, MSF activates the inflammation-associated transcription factor NFκB, resulting in the onset of autophagy/mitophagy, thereby driving glycolytic metabolism (L-lactate production) in the tumor microenvironment. Consistent with the idea that glycolytic fibroblasts fuel tumor growth (via L-lactate, a high-energy mitochondrial fuel), MSF fibroblasts significantly increased tumor growth, by up to 4-fold. Mechanistic dissection of the MSF signaling pathway indicated that Cdc42 lies downstream of MSF and fibroblast activation. In accordance with this notion, Cdc42 overexpression in immortalized fibroblasts was sufficient to drive myofibroblast differentiation, to provoke a shift towards glycolytic metabolism and to promote tumor growth by up to 2-fold. In conclusion, the MSF/Cdc42/NFκB signaling cascade may be a critical druggable target in preventing “Warburg-like” cancer metabolism in tumor-associated fibroblasts. Thus, MSF functions in the metabolic remodeling of the tumor microenvironment by metabolically reprogramming cancer-associated fibroblasts toward glycolytic metabolism.</subfield>
        </datafield>
        <datafield tag="856" ind1="4" ind2="">
            
            <subfield code="u">http://dx.doi.org/10.4161/cc.21701</subfield>
            <subfield code="u">http://www.landesbioscience.com/journals/cc/article/21701/</subfield>
        </datafield>
 
        <datafield tag="949" ind1="" ind2="">
            <subfield code="t">article</subfield>
            <subfield code="n">Report</subfield>
        </datafield>
    </mx:record>
    <mx:record id="21730">
        <mx:leader/>
        <datafield tag="022" ind1="" ind2="">
            <subfield code="a">1538-4101</subfield>
        </datafield>
        <datafield tag="100" ind1="" ind2="">
            <subfield code="a">Raffaele La Montagna</subfield>
            <subfield code="a">Isabella Caligiuri</subfield>
            <subfield code="a">Pasquale Maranta</subfield>
            <subfield code="a">Chiara Lucchetti</subfield>
            <subfield code="a">Luca Esposito</subfield>
            <subfield code="a">Marco G. Paggi</subfield>
            <subfield code="a">Giuseppe Toffoli</subfield>
            <subfield code="a">Flavio Rizzolio and Antonio Giordano</subfield>
        </datafield>
        
        <datafield tag="210" ind1="" ind2="">
            <subfield code="a">cc</subfield>
        </datafield>
        
        <datafield tag="245" ind1="" ind2="">
            <subfield code="a">Androgen receptor serine 81 mediates Pin1 interaction and activity</subfield> 
        </datafield>
        
        <datafield tag="260" ind1="3" ind2="">
            <subfield code="b">Landes Bioscience</subfield>
            <subfield code="c">2012-09-15</subfield>
        </datafield>
        
        <datafield tag="302" ind1="" ind2="">
            <subfield code="a">3415 - 3420</subfield>
        </datafield>
        
        <datafield tag="440" ind1="" ind2="">
            
            <subfield code="a">Cell Cycle</subfield>
            <subfield code="v">11-18</subfield>
        </datafield>
        <datafield tag="449" ind1="" ind2="">
            <subfield code="o">Landes Bioscience</subfield>
        </datafield>
        <datafield tag="520" ind1="3" ind2="">
            <subfield code="a">Hormone-dependent tumors are characterized by deregulated activity of specific steroid receptors, allowing aberrant expression of many genes involved in cancer initiation, progression and metastasis. In prostate cancer, the androgen receptor (AR) protein has pivotal functions, and over the years it has been the target of different drugs. AR is a nuclear receptor whose activity is regulated by a phosphorylation mechanism controlled by hormone and growth factors. Following phosphorylation, AR interacts with many cofactors that closely control its function. Among such cofactors, Pin1 is a peptidyl-prolyl isomerase that is involved in the control of protein phosphorylation and has a prognostic value in prostate cancer. In the present study, we demonstrate that ARSer81 is involved in the interaction with Pin1, and that this interaction is important for the transcriptional activity of AR. Since Pin1 expression positively correlates with tumor grade, our results suggest that Pin1 can participate in this process by modulating AR function.</subfield>
        </datafield>
        <datafield tag="856" ind1="4" ind2="">
            
            <subfield code="u">http://dx.doi.org/10.4161/cc.21730</subfield>
            <subfield code="u">http://www.landesbioscience.com/journals/cc/article/21730/</subfield>
        </datafield>
 
        <datafield tag="949" ind1="" ind2="">
            <subfield code="t">article</subfield>
            <subfield code="n">Report</subfield>
        </datafield>
    </mx:record>
    <mx:record id="21731">
        <mx:leader/>
        <datafield tag="022" ind1="" ind2="">
            <subfield code="a">1538-4101</subfield>
        </datafield>
        <datafield tag="100" ind1="" ind2="">
            <subfield code="a">Jennifer McQueen</subfield>
            <subfield code="a">Dewald van Dyk</subfield>
            <subfield code="a">Barry Young</subfield>
            <subfield code="a">Chris Loewen and Vivien Measday</subfield>
        </datafield>
        
        <datafield tag="210" ind1="" ind2="">
            <subfield code="a">cc</subfield>
        </datafield>
        
        <datafield tag="245" ind1="" ind2="">
            <subfield code="a">The Mck1 GSK-3 kinase inhibits the activity of Clb2-Cdk1 post-nuclear division</subfield> 
        </datafield>
        
        <datafield tag="260" ind1="3" ind2="">
            <subfield code="b">Landes Bioscience</subfield>
            <subfield code="c">2012-09-15</subfield>
        </datafield>
        
        <datafield tag="302" ind1="" ind2="">
            <subfield code="a">3421 - 3432</subfield>
        </datafield>
        
        <datafield tag="440" ind1="" ind2="">
            
            <subfield code="a">Cell Cycle</subfield>
            <subfield code="v">11-18</subfield>
        </datafield>
        <datafield tag="449" ind1="" ind2="">
            <subfield code="o">Landes Bioscience</subfield>
        </datafield>
        <datafield tag="520" ind1="3" ind2="">
            <subfield code="a">The glycogen synthase kinase-3 homolog, Mck1, has been implicated in many cellular functions, from sporulation to calcium stress response in budding yeast. Here, we report a novel function for Mck1 in the inhibition of Clb2-Cdk1 activity post nuclear division. Clb2-Cdk1, the major mitotic cyclin-Cdk complex in yeast, accumulates before anaphase and must be inhibited in telophase for cells to exit mitosis and enter into the next cell cycle. We show that the &lt;em&gt;mck1Δ&lt;/em&gt; mutant is highly sensitive to increased Clb2-Cdk1 activity caused either by overexpression of Clb2 or the Cdk1-activating phosphatase Mih1. Deletion of the Cdk1 inhibitory kinase, &lt;em&gt;SWE1&lt;/em&gt;, in combination with a &lt;em&gt;mck1Δ&lt;/em&gt; mutant results in a synthetic growth defect, suggesting that Mck1 and Swe1 function in parallel pathways to inhibit Clb2-Cdk1. We find that &lt;em&gt;mck1Δ&lt;/em&gt; strains have a delay in mitotic exit as well as elevated levels of Clb2-Cdk1 activity post-nuclear division. Using a co-immunoprecipitation assay, we identify a physical interaction between Mck1 and both Clb2 and Mih1. Finally, we demonstrate that phosphorylation of purified Clb2 by Cdk1 is inhibited by catalytically active Mck1 but not catalytically inactive Mck1 in vitro. We propose that Mck1 inhibits the activity of Clb2-Cdk1 via interaction with Clb2. The mammalian glycogen synthase kinase-3 homolog has been implicated in cyclin inhibition, suggesting a conserved cell cycle function for both yeast and mammalian glycogen synthase kinases.</subfield>
        </datafield>
        <datafield tag="856" ind1="4" ind2="">
            
            <subfield code="u">http://dx.doi.org/10.4161/cc.21731</subfield>
            <subfield code="u">http://www.landesbioscience.com/journals/cc/article/21731/</subfield>
        </datafield>
 
        <datafield tag="949" ind1="" ind2="">
            <subfield code="t">article</subfield>
            <subfield code="n">Report</subfield>
        </datafield>
    </mx:record>
    <mx:record id="21732">
        <mx:leader/>
        <datafield tag="022" ind1="" ind2="">
            <subfield code="a">1538-4101</subfield>
        </datafield>
        <datafield tag="100" ind1="" ind2="">
            <subfield code="a">Chun-Chi Wu</subfield>
            <subfield code="a">Tsung-Ying Yang</subfield>
            <subfield code="a">Chang-Tze Ricky Yu</subfield>
            <subfield code="a">Liem Phan</subfield>
            <subfield code="a">Cristina Ivan</subfield>
            <subfield code="a">Anil K. Sood</subfield>
            <subfield code="a">Shih-Lan Hsu and Mong-Hong Lee</subfield>
        </datafield>
        
        <datafield tag="210" ind1="" ind2="">
            <subfield code="a">cc</subfield>
        </datafield>
        
        <datafield tag="245" ind1="" ind2="">
            <subfield code="a">p53 negatively regulates Aurora A via both transcriptional and posttranslational regulation</subfield> 
        </datafield>
        
        <datafield tag="260" ind1="3" ind2="">
            <subfield code="b">Landes Bioscience</subfield>
            <subfield code="c">2012-09-15</subfield>
        </datafield>
        
        <datafield tag="302" ind1="" ind2="">
            <subfield code="a">3433 - 3442</subfield>
        </datafield>
        
        <datafield tag="440" ind1="" ind2="">
            
            <subfield code="a">Cell Cycle</subfield>
            <subfield code="v">11-18</subfield>
        </datafield>
        <datafield tag="449" ind1="" ind2="">
            <subfield code="o">Landes Bioscience</subfield>
        </datafield>
        <datafield tag="520" ind1="3" ind2="">
            <subfield code="a">p53 plays an important role in mitotic checkpoint, but what its role is remains enigmatic. Aurora A is a Ser/Thr kinase involved in correcting progression of mitosis. Here, we show that p53 is a negative regulator for Aurora A. We found that p53 deficiency leads to Aurora A elevation. Ectopic expression of p53 or DNA damage-induced expression of p53 can suppress the expression of Aurora A. Mechanistic studies show that p53 is a negative regulator for Aurora A expression through both transcriptional and posttranslational regulation. p53 knockdown in cancer cells reduces the level of p21, which, in turn, increases the activity of CDK2 followed by induction of Rb1 hyperphosphorylation and its dissociation with transcriptional factor E2F3. E2F3 can bind to Aurora A gene promoter, potentiating Aurora A gene expression and p53 deficiency, enhancing the binding of E2F3 on Aurora A promoter. Also, p53 deficiency leads to decelerating Aurora A’s turnover rate, due to the fact that p53 deficiency causes the downregulation of Fbw7α, a component of E3 ligase of Aurora A. Consistently, p53 knockdown-mediated Aurora A elevation is mitigated when Fbw7α is ectopically expressed. Thus, p53-mediated Aurora A degradation requires Fbw7α expression. Significantly, inverse correlation between p53 and Aurora A elevation is translated into the deregulation of centrosome amplification. p53 knockdown leads to high percentages of cells with abnormal amplification of centrosome. These data suggest that p53 is an important negative regulator of Aurora A, and that loss of p53 in many types of cancer could lead to abnormal elevation of Aurora A and dysregulated mitosis, which provides a growth advantage for cancer cells.</subfield>
        </datafield>
        <datafield tag="856" ind1="4" ind2="">
            
            <subfield code="u">http://dx.doi.org/10.4161/cc.21732</subfield>
            <subfield code="u">http://www.landesbioscience.com/journals/cc/article/21732/</subfield>
        </datafield>
 
        <datafield tag="949" ind1="" ind2="">
            <subfield code="t">article</subfield>
            <subfield code="n">Report</subfield>
        </datafield>
    </mx:record>
    <mx:record id="21754">
        <mx:leader/>
        <datafield tag="022" ind1="" ind2="">
            <subfield code="a">1538-4101</subfield>
        </datafield>
        <datafield tag="100" ind1="" ind2="">
            <subfield code="a">Michelle T. Burstein</subfield>
            <subfield code="a">Pavlo Kyryakov</subfield>
            <subfield code="a">Adam Beach</subfield>
            <subfield code="a">Vincent R. Richard</subfield>
            <subfield code="a">Olivia Koupaki</subfield>
            <subfield code="a">Alejandra Gomez-Perez</subfield>
            <subfield code="a">Anna Leonov</subfield>
            <subfield code="a">Sean Levy</subfield>
            <subfield code="a">Forough Noohi and Vladimir I. Titorenko</subfield>
        </datafield>
        
        <datafield tag="210" ind1="" ind2="">
            <subfield code="a">cc</subfield>
        </datafield>
        
        <datafield tag="245" ind1="" ind2="">
            <subfield code="a">Lithocholic acid extends longevity of chronologically aging yeast only if added at certain critical periods of their lifespan</subfield> 
        </datafield>
        
        <datafield tag="260" ind1="3" ind2="">
            <subfield code="b">Landes Bioscience</subfield>
            <subfield code="c">2012-09-15</subfield>
        </datafield>
        
        <datafield tag="302" ind1="" ind2="">
            <subfield code="a">3443 - 3462</subfield>
        </datafield>
        
        <datafield tag="440" ind1="" ind2="">
            
            <subfield code="a">Cell Cycle</subfield>
            <subfield code="v">11-18</subfield>
        </datafield>
        <datafield tag="449" ind1="" ind2="">
            <subfield code="o">Landes Bioscience</subfield>
        </datafield>
        <datafield tag="520" ind1="3" ind2="">
            <subfield code="a">Our studies revealed that LCA (lithocholic bile acid) extends yeast chronological lifespan if added to growth medium at the time of cell inoculation. We also demonstrated that longevity in chronologically aging yeast is programmed by the level of metabolic capacity and organelle organization that they developed before entering a quiescent state and, thus, that chronological aging in yeast is likely to be the final step of a developmental program progressing through at least one checkpoint prior to entry into quiescence. Here, we investigate how LCA influences longevity and several longevity-defining cellular processes in chronologically aging yeast if added to growth medium at different periods of the lifespan. We found that LCA can extend longevity of yeast under CR (caloric restriction) conditions only if added at either of two lifespan periods. One of them includes logarithmic and diauxic growth phases, whereas the other period exists in early stationary phase. Our findings suggest a mechanism linking the ability of LCA to increase the lifespan of CR yeast only if added at either of the two periods to its differential effects on various longevity-defining processes. In this mechanism, LCA controls these processes at three checkpoints that exist in logarithmic/diauxic, post-diauxic and early stationary phases. We therefore hypothesize that a biomolecular longevity network progresses through a series of checkpoints, at each of which (1) genetic, dietary and pharmacological anti-aging interventions modulate a distinct set of longevity-defining processes comprising the network; and (2) checkpoint-specific master regulators monitor and govern the functional states of these processes.</subfield>
        </datafield>
        <datafield tag="856" ind1="4" ind2="">
            
            <subfield code="u">http://dx.doi.org/10.4161/cc.21754</subfield>
            <subfield code="u">http://www.landesbioscience.com/journals/cc/article/21754/</subfield>
        </datafield>
 
        <datafield tag="949" ind1="" ind2="">
            <subfield code="t">article</subfield>
            <subfield code="n">Report</subfield>
        </datafield>
    </mx:record>
    <mx:record id="21770">
        <mx:leader/>
        <datafield tag="022" ind1="" ind2="">
            <subfield code="a">1538-4101</subfield>
        </datafield>
        <datafield tag="100" ind1="" ind2="">
            <subfield code="a">Zeng-Fu Shang</subfield>
            <subfield code="a">Lan Yu</subfield>
            <subfield code="a">Bing Li</subfield>
            <subfield code="a">Wen-Zhi Tu</subfield>
            <subfield code="a">Yu Wang</subfield>
            <subfield code="a">Xiao-Dan Liu</subfield>
            <subfield code="a">Hua Guan</subfield>
            <subfield code="a">Bo Huang</subfield>
            <subfield code="a">Wei-Qing Rang and Ping-Kun Zhou</subfield>
        </datafield>
        
        <datafield tag="210" ind1="" ind2="">
            <subfield code="a">cc</subfield>
        </datafield>
        
        <datafield tag="245" ind1="" ind2="">
            <subfield code="a">4E-BP1 participates in maintaining spindle integrity and genomic stability via interacting with PLK1</subfield> 
        </datafield>
        
        <datafield tag="260" ind1="3" ind2="">
            <subfield code="b">Landes Bioscience</subfield>
            <subfield code="c">2012-09-15</subfield>
        </datafield>
        
        <datafield tag="302" ind1="" ind2="">
            <subfield code="a">3463 - 3471</subfield>
        </datafield>
        
        <datafield tag="440" ind1="" ind2="">
            
            <subfield code="a">Cell Cycle</subfield>
            <subfield code="v">11-18</subfield>
        </datafield>
        <datafield tag="449" ind1="" ind2="">
            <subfield code="o">Landes Bioscience</subfield>
        </datafield>
        <datafield tag="520" ind1="3" ind2="">
            <subfield code="a">The essential function of eIF4E-binding protein 1 (4E-BP1) in translation initiation has been well established; however, the role of 4E-BP1 in normal cell cycle progression is coming to attention. Here, we revealed the role of 4E-BP1 on mitotic regulation and chromosomal DNA dynamics during mitosis. First, we have observed the co-localization of the phosphorylated 4E-BP1 at T37/46 with Polo-like kinase 1 (PLK1) at the centrosomes during. Depression of 4E-BP1 by small interfering RNA in HepG2 or HeLa cells resulted in an increased outcome of polyploidy and aberrant mitosis, including chromosomal DNA misaligned and multi-polar spindles or multiple centrosomes. We observed that 4E-BP1 interacted with PLK1 directly in vitro and in vivo in mitotic cells, and the C-terminal aa 77–118 of 4E-BP1 mediates its interaction with PLK1. PLK1 can phosphorylate 4E-BP1 in vitro. Furthermore, the depletion of 4E-BP1 sensitized HepG2 and HeLa cells to the microtubule disruption agent paclitaxel. These results demonstrate that 4E-BP1, beyond its role in translation regulation, can function as a regulator of mitosis via interacting with PLK1, and possibly plays a role in genomic stability maintaining.</subfield>
        </datafield>
        <datafield tag="856" ind1="4" ind2="">
            
            <subfield code="u">http://dx.doi.org/10.4161/cc.21770</subfield>
            <subfield code="u">http://www.landesbioscience.com/journals/cc/article/21770/</subfield>
        </datafield>
 
        <datafield tag="949" ind1="" ind2="">
            <subfield code="t">article</subfield>
            <subfield code="n">Report</subfield>
        </datafield>
    </mx:record>
    <mx:record id="21771">
        <mx:leader/>
        <datafield tag="022" ind1="" ind2="">
            <subfield code="a">1538-4101</subfield>
        </datafield>
        <datafield tag="100" ind1="" ind2="">
            <subfield code="a">Shobhan Gaddameedhi</subfield>
            <subfield code="a">Joyce T. Reardon</subfield>
            <subfield code="a">Rui Ye</subfield>
            <subfield code="a">Nuri Ozturk and Aziz Sancar</subfield>
        </datafield>
        
        <datafield tag="210" ind1="" ind2="">
            <subfield code="a">cc</subfield>
        </datafield>
        
        <datafield tag="245" ind1="" ind2="">
            <subfield code="a">Effect of circadian clock mutations on DNA damage response in mammalian cells</subfield> 
        </datafield>
        
        <datafield tag="260" ind1="3" ind2="">
            <subfield code="b">Landes Bioscience</subfield>
            <subfield code="c">2012-09-15</subfield>
        </datafield>
        
        <datafield tag="302" ind1="" ind2="">
            <subfield code="a">3481 - 3491</subfield>
        </datafield>
        
        <datafield tag="440" ind1="" ind2="">
            
            <subfield code="a">Cell Cycle</subfield>
            <subfield code="v">11-18</subfield>
        </datafield>
        <datafield tag="449" ind1="" ind2="">
            <subfield code="o">Landes Bioscience</subfield>
        </datafield>
        <datafield tag="520" ind1="3" ind2="">
            <subfield code="a">The circadian clock is a global regulatory mechanism that confers daily rhythmicity on many biochemical and physiological functions, including DNA excision repair in mammalian organisms. Here, we investigated the effect of the circadian clock on the major DNA damage response pathways by using mouse cell lines mutated in genes encoding proteins in the positive (Bmal1, CLOCK) or negative (Cry 1/2, Per 1/2) arms of the transcription-translation feedback loop that generates the circadian clock. We find that cells mutated in these genes are indistinguishable from wild-type in their response to UV, ionizing radiation and mitomycin C. We conclude that either the majority of DNA damage response reactions are not controlled by the circadian clock or that, even if such a control exists at the organism level, it is supplanted by homeostatic control mechanisms at the cellular level in tissue culture. We suggest that caution must be exercised in extrapolating from experiments in tissue culture to whole animals with respect to the effect of the circadian clock on cellular response to DNA damaging agents.</subfield>
        </datafield>
        <datafield tag="856" ind1="4" ind2="">
            
            <subfield code="u">http://dx.doi.org/10.4161/cc.21771</subfield>
            <subfield code="u">http://www.landesbioscience.com/journals/cc/article/21771/</subfield>
        </datafield>
 
        <datafield tag="949" ind1="" ind2="">
            <subfield code="t">article</subfield>
            <subfield code="n">Report</subfield>
        </datafield>
    </mx:record>
    <mx:record id="21789">
        <mx:leader/>
        <datafield tag="022" ind1="" ind2="">
            <subfield code="a">1538-4101</subfield>
        </datafield>
        <datafield tag="100" ind1="" ind2="">
            <subfield code="a">Lorenzo Galluzzi</subfield>
            <subfield code="a">Ilio Vitale</subfield>
            <subfield code="a">Laura Senovilla</subfield>
            <subfield code="a">Tobias Eisenberg</subfield>
            <subfield code="a">Didac Carmona-Gutiérrez</subfield>
            <subfield code="a">Erika Vacchelli</subfield>
            <subfield code="a">Thomas Robert</subfield>
            <subfield code="a">Hugues Ripoche</subfield>
            <subfield code="a">Nora Jägemann</subfield>
            <subfield code="a">Caroline Paccard</subfield>
            <subfield code="a">Nicolas Servant</subfield>
            <subfield code="a">Philippe Hupé</subfield>
            <subfield code="a">Vladimir Lazar</subfield>
            <subfield code="a">Philippe Dessen</subfield>
            <subfield code="a">Emmanuel Barillot</subfield>
            <subfield code="a">Hans Zischka</subfield>
            <subfield code="a">Frank Madeo and Guido Kroemer</subfield>
        </datafield>
        
        <datafield tag="210" ind1="" ind2="">
            <subfield code="a">cc</subfield>
        </datafield>
        
        <datafield tag="245" ind1="" ind2="">
            <subfield code="a">Independent transcriptional reprogramming and apoptosis induction by cisplatin</subfield> 
        </datafield>
        
        <datafield tag="260" ind1="3" ind2="">
            <subfield code="b">Landes Bioscience</subfield>
            <subfield code="c">2012-09-15</subfield>
        </datafield>
        
        <datafield tag="302" ind1="" ind2="">
            <subfield code="a">3472 - 3480</subfield>
        </datafield>
        
        <datafield tag="440" ind1="" ind2="">
            
            <subfield code="a">Cell Cycle</subfield>
            <subfield code="v">11-18</subfield>
        </datafield>
        <datafield tag="449" ind1="" ind2="">
            <subfield code="o">Landes Bioscience</subfield>
        </datafield>
        <datafield tag="520" ind1="3" ind2="">
            <subfield code="a">Neither the molecular mechanisms whereby cancer cells intrinsically are or become resistant to the DNA-damaging agent cisplatin nor the signaling pathways that account for cisplatin cytotoxicity have thus far been characterized in detail. In an attempt to gain further insights into the molecular cascades elicited by cisplatin (leading to resistance or underpinning its antineoplastic properties), we comparatively investigated the ability of cisplatin, C2-ceramide and cadmium dichloride, alone or in the presence of an array of mitochondrion-protective agents, to trigger the permeabilization of purified mitochondria. In addition, we compared the transcriptional response triggered by cisplatin, C2-ceramide and cadmium dichloride in non-small cell lung carcinoma A549 cells. Finally, we assessed the capacity of cisplatin, C2-ceramide and cadmium dichloride to reduce the clonogenic potential of a battery of yeast strains lacking proteins involved in the regulation of cell death, DNA damage signaling and stress management. This multipronged experimental approach revealed that cisplatin elicits signaling pathways that are for the most part “private,” i.e., that manifest limited overlap with the molecular cascades ignited by other inducers of mitochondrial apoptosis, and triggers apoptosis mainly in a transcription-independent fashion. Indeed, bona fide cisplatin-response modifiers that we have recently identified by a functional genome-wide siRNA screen are either not transcriptionally regulated during cisplatin-induced cell death or their transcriptional modulation reflects the activation of an adaptive response promoting cisplatin resistance</subfield>
        </datafield>
        <datafield tag="856" ind1="4" ind2="">
            
            <subfield code="u">http://dx.doi.org/10.4161/cc.21789</subfield>
            <subfield code="u">http://www.landesbioscience.com/journals/cc/article/21789/</subfield>
        </datafield>
 
        <datafield tag="949" ind1="" ind2="">
            <subfield code="t">article</subfield>
            <subfield code="n">Report</subfield>
        </datafield>
    </mx:record>
    <mx:record id="21801">
        <mx:leader/>
        <datafield tag="022" ind1="" ind2="">
            <subfield code="a">1538-4101</subfield>
        </datafield>
        <datafield tag="100" ind1="" ind2="">
            <subfield code="a">Kadin Karakaya</subfield>
            <subfield code="a">Friederike Herbst</subfield>
            <subfield code="a">Claudia Ball</subfield>
            <subfield code="a">Hanno Glimm</subfield>
            <subfield code="a">Alwin Krämer and Harald Löffler</subfield>
        </datafield>
        
        <datafield tag="210" ind1="" ind2="">
            <subfield code="a">cc</subfield>
        </datafield>
        
        <datafield tag="245" ind1="" ind2="">
            <subfield code="a">Overexpression of EVI1 interferes with cytokinesis and leads to accumulation of cells with supernumerary centrosomes in G&lt;sub&gt;0/1&lt;/sub&gt; phase</subfield> 
        </datafield>
        
        <datafield tag="260" ind1="3" ind2="">
            <subfield code="b">Landes Bioscience</subfield>
            <subfield code="c">2012-09-15</subfield>
        </datafield>
        
        <datafield tag="302" ind1="" ind2="">
            <subfield code="a">3492 - 3503</subfield>
        </datafield>
        
        <datafield tag="440" ind1="" ind2="">
            
            <subfield code="a">Cell Cycle</subfield>
            <subfield code="v">11-18</subfield>
        </datafield>
        <datafield tag="449" ind1="" ind2="">
            <subfield code="o">Landes Bioscience</subfield>
        </datafield>
        <datafield tag="520" ind1="3" ind2="">
            <subfield code="a">Ectopic viral integration site 1 (EVI1), a transcription factor frequently overexpressed in myeloid neoplasias, has been implicated in the generation of malignancy-associated centrosomal aberrations and chromosomal instability. Here, we sought to investigate the underlying cause of centrosome amplification in EVI1-overexpressing cells. We found that overexpression of EVI1-HA in U2OS cells induced supernumerary centrosomes, which were consistently associated with enlarged nuclei or binuclear cells. Live cell imaging experiments identified cytokinesis failure as the underlying cause of this phenotype. In accordance with previous reports, EVI1 overexpression induced a partial cell cycle arrest in G&lt;sub&gt;0/1&lt;/sub&gt; phase, accompanied by elevated cyclin D1 and p21 levels, reduced Cdk2 activity and activation of the p53 pathway. Supernumerary centrosomes predominantly occurred in resting cells, as identified by low levels of the proliferation marker K&lt;sub&gt;i&lt;/sub&gt;-67, leading to the conclusion that they result from tetraploidization after cytokinesis failure and are confined to G&lt;sub&gt;0/1&lt;/sub&gt;-arrested tetraploid cells. Depletion of p53 using siRNA revealed that further polyploidization of these cells was inhibited by the p53-dependent tetraploidy checkpoint.</subfield>
        </datafield>
        <datafield tag="856" ind1="4" ind2="">
            
            <subfield code="u">http://dx.doi.org/10.4161/cc.21801</subfield>
            <subfield code="u">http://www.landesbioscience.com/journals/cc/article/21801/</subfield>
        </datafield>
 
        <datafield tag="949" ind1="" ind2="">
            <subfield code="t">article</subfield>
            <subfield code="n">Report</subfield>
        </datafield>
    </mx:record>
    <mx:record id="21802">
        <mx:leader/>
        <datafield tag="022" ind1="" ind2="">
            <subfield code="a">1538-4101</subfield>
        </datafield>
        <datafield tag="100" ind1="" ind2="">
            <subfield code="a">Yen K. Lieu and E. Premkumar Reddy</subfield>
        </datafield>
        
        <datafield tag="210" ind1="" ind2="">
            <subfield code="a">cc</subfield>
        </datafield>
        
        <datafield tag="245" ind1="" ind2="">
            <subfield code="a">Impaired adult myeloid progenitor CMP and GMP cell function in conditional c-&lt;italic&gt;&lt;em&gt;myb&lt;/em&gt;&lt;/italic&gt;-knockout mice</subfield> 
        </datafield>
        
        <datafield tag="260" ind1="3" ind2="">
            <subfield code="b">Landes Bioscience</subfield>
            <subfield code="c">2012-09-15</subfield>
        </datafield>
        
        <datafield tag="302" ind1="" ind2="">
            <subfield code="a">3504 - 3512</subfield>
        </datafield>
        
        <datafield tag="440" ind1="" ind2="">
            
            <subfield code="a">Cell Cycle</subfield>
            <subfield code="v">11-18</subfield>
        </datafield>
        <datafield tag="449" ind1="" ind2="">
            <subfield code="o">Landes Bioscience</subfield>
        </datafield>
        <datafield tag="520" ind1="3" ind2="">
            <subfield code="a">The differentiation of myeloid progenitors to mature, terminally differentiated cells is a highly regulated process. Here, we showed that conditional disruption of the c-&lt;em&gt;myb&lt;/em&gt; proto-oncogene in adult mice resulted in dramatic reductions in CMP, GMP and MEP myeloid progenitors, leading to a reduction of neutrophils, basophils, monocytes and platelets in peripheral blood. In addition, c-&lt;em&gt;myb&lt;/em&gt; plays a critical role at multiple stages of myeloid development, from multipotent CMP and bipotent GMP to unipotent CFU-G and CFU-M progenitor cells. c-&lt;em&gt;myb&lt;/em&gt; controls the differentiation of these cells and is required for the proper commitment, maturation and normal differentiation of CMPs and GMPs. Specifically, c-&lt;em&gt;myb&lt;/em&gt; regulates the precise commitment to the megakaryocytic and granulo-monocytic pathways and governs the granulocytic-monocytic lineage choice. c-&lt;em&gt;myb&lt;/em&gt; is also required for the commitment along the granulocytic pathway for early myeloid progenitor cells and for the maturation of committed precursor cells along this pathway. On the other hand, disruption of the c-&lt;em&gt;myb&lt;/em&gt; gene favors the commitment to the monocytic lineage, although monocytic development was abnormal with cells appearing more mature with atypical CD41 surface markers. These results demonstrate that c-&lt;em&gt;myb&lt;/em&gt; plays a pivotal role in the regulation of multiple stages in adult myelogenesis.</subfield>
        </datafield>
        <datafield tag="856" ind1="4" ind2="">
            
            <subfield code="u">http://dx.doi.org/10.4161/cc.21802</subfield>
            <subfield code="u">http://www.landesbioscience.com/journals/cc/article/21802/</subfield>
        </datafield>
 
        <datafield tag="949" ind1="" ind2="">
            <subfield code="t">article</subfield>
            <subfield code="n">Report</subfield>
        </datafield>
    </mx:record>
    <mx:record id="21803">
        <mx:leader/>
        <datafield tag="022" ind1="" ind2="">
            <subfield code="a">1538-4101</subfield>
        </datafield>
        <datafield tag="100" ind1="" ind2="">
            <subfield code="a">Yasuyuki Amoh</subfield>
            <subfield code="a">Sumiyuki Mii</subfield>
            <subfield code="a">Ryoichi Aki</subfield>
            <subfield code="a">Yuko Hamada</subfield>
            <subfield code="a">Katsumasa Kawahara</subfield>
            <subfield code="a">Robert M. Hoffman and Kensei Katsuoka</subfield>
        </datafield>
        
        <datafield tag="210" ind1="" ind2="">
            <subfield code="a">cc</subfield>
        </datafield>
        
        <datafield tag="245" ind1="" ind2="">
            <subfield code="a">Multipotent nestin-expressing stem cells capable of forming neurons are located in the upper, middle and lower part of the vibrissa hair follicle</subfield> 
        </datafield>
        
        <datafield tag="260" ind1="3" ind2="">
            <subfield code="b">Landes Bioscience</subfield>
            <subfield code="c">2012-09-15</subfield>
        </datafield>
        
        <datafield tag="302" ind1="" ind2="">
            <subfield code="a">3513 - 3517</subfield>
        </datafield>
        
        <datafield tag="440" ind1="" ind2="">
            
            <subfield code="a">Cell Cycle</subfield>
            <subfield code="v">11-18</subfield>
        </datafield>
        <datafield tag="449" ind1="" ind2="">
            <subfield code="o">Landes Bioscience</subfield>
        </datafield>
        <datafield tag="520" ind1="3" ind2="">
            <subfield code="a">We have previously demonstrated that the neural stem-cell marker nestin is expressed in hair follicle stem cells. Nestin-expressing cells were initially identified in the hair follicle bulge area (BA) using a transgenic mouse model in which the nestin promoter drives the green fluorescent protein (ND-GFP). The hair-follicle ND-GFP-expressing cells are keratin 15-negative and CD34-positive and could differentiate to neurons, glia, keratinocytes, smooth muscle cells and melanocytes in vitro. Subsequently, we showed that the nestin-expressing stem cells could affect nerve and spinal cord regeneration after injection in mouse models. In the present study, we separated the mouse vibrissa hair follicle into three parts (upper, middle and lower). Each part of the follicle was cultured separately in DMEM-F12 containing B-27 and 1% methylcellulose supplemented with basic FGF. After 2 mo, the nestin-expressing cells from each of the separated parts of the hair follicle proliferated and formed spheres. Upon transfer of the spheres to RPMI 1640 medium containing 10% FBS, the nestin-expressing cells in the spheres differentiated to neurons, as well as glia, keratinocytes, smooth muscle cells and melanocytes. The differentiated cells were produced by spheres which formed from nestin-expressing cells from all segments of the hair follicle. However, the differentiation potential is greatest in the upper part of the follicle. This result is consistent with trafficking of nestin-expressing cells throughout the hair follicle from the bulge area to the dermal papilla that we previously observed. The nestin-expressing cells from the upper part of the follicle produced spheres in very large amounts, which in turn differentiated to neurons and other cell types. The results of the present study demonstrate that multipotent, nestin-expressing stem cells are present throughout the hair follicle and that the upper part of the follicle can produce the stem cells in large amounts that could be used for nerve and spinal cord repair.</subfield>
        </datafield>
        <datafield tag="856" ind1="4" ind2="">
            
            <subfield code="u">http://dx.doi.org/10.4161/cc.21803</subfield>
            <subfield code="u">http://www.landesbioscience.com/journals/cc/article/21803/</subfield>
        </datafield>
 
        <datafield tag="949" ind1="" ind2="">
            <subfield code="t">article</subfield>
            <subfield code="n">Report</subfield>
        </datafield>
    </mx:record>
    <mx:record id="21840">
        <mx:leader/>
        <datafield tag="022" ind1="" ind2="">
            <subfield code="a">1538-4101</subfield>
        </datafield>
        <datafield tag="100" ind1="" ind2="">
            <subfield code="a">Manel Joaquin</subfield>
            <subfield code="a">Albert Gubern and Francesc Posas</subfield>
        </datafield>
        
        <datafield tag="210" ind1="" ind2="">
            <subfield code="a">cc</subfield>
        </datafield>
        
        <datafield tag="245" ind1="" ind2="">
            <subfield code="a">A novel G&lt;sub&gt;1&lt;/sub&gt; checkpoint mediated by the p57 CDK inhibitor and p38 SAPK promotes cell survival upon stress</subfield> 
        </datafield>
        
        <datafield tag="260" ind1="3" ind2="">
            <subfield code="b">Landes Bioscience</subfield>
            <subfield code="c">2012-09-15</subfield>
        </datafield>
        
        <datafield tag="302" ind1="" ind2="">
            <subfield code="a">3339 - 3340</subfield>
        </datafield>
        
        <datafield tag="440" ind1="" ind2="">
            
            <subfield code="a">Cell Cycle</subfield>
            <subfield code="v">11-18</subfield>
        </datafield>
        <datafield tag="449" ind1="" ind2="">
            <subfield code="o">Landes Bioscience</subfield>
        </datafield>
        <datafield tag="520" ind1="3" ind2="">
            <subfield code="a">Comment on: Joaquin M, et al. EMBO J 2012; 31:2952-64.</subfield>
        </datafield>
        <datafield tag="856" ind1="4" ind2="">
            
            <subfield code="u">http://dx.doi.org/10.4161/cc.21840</subfield>
            <subfield code="u">http://www.landesbioscience.com/journals/cc/article/21840/</subfield>
        </datafield>
 
        <datafield tag="949" ind1="" ind2="">
            <subfield code="t">article</subfield>
            <subfield code="n">Editorials: Cell Cycle Features</subfield>
        </datafield>
    </mx:record>
    <mx:record id="21841">
        <mx:leader/>
        <datafield tag="022" ind1="" ind2="">
            <subfield code="a">1538-4101</subfield>
        </datafield>
        <datafield tag="100" ind1="" ind2="">
            <subfield code="a">Andrei L. Gartel</subfield>
        </datafield>
        
        <datafield tag="210" ind1="" ind2="">
            <subfield code="a">cc</subfield>
        </datafield>
        
        <datafield tag="245" ind1="" ind2="">
            <subfield code="a">The oncogenic transcription factor FOXM1 and anticancer therapy</subfield> 
        </datafield>
        
        <datafield tag="260" ind1="3" ind2="">
            <subfield code="b">Landes Bioscience</subfield>
            <subfield code="c">2012-09-15</subfield>
        </datafield>
        
        <datafield tag="302" ind1="" ind2="">
            <subfield code="a">3341 - 3342</subfield>
        </datafield>
        
        <datafield tag="440" ind1="" ind2="">
            
            <subfield code="a">Cell Cycle</subfield>
            <subfield code="v">11-18</subfield>
        </datafield>
        <datafield tag="449" ind1="" ind2="">
            <subfield code="o">Landes Bioscience</subfield>
        </datafield>
        <datafield tag="520" ind1="3" ind2="">
            <subfield code="a">Comment on: Halasi M,et al. PLoS One 2012; 7:e31761.</subfield>
        </datafield>
        <datafield tag="856" ind1="4" ind2="">
            
            <subfield code="u">http://dx.doi.org/10.4161/cc.21841</subfield>
            <subfield code="u">http://www.landesbioscience.com/journals/cc/article/21841/</subfield>
        </datafield>
 
        <datafield tag="949" ind1="" ind2="">
            <subfield code="t">article</subfield>
            <subfield code="n">Editorials: Cell Cycle Features</subfield>
        </datafield>
    </mx:record>
    <mx:record id="21875">
        <mx:leader/>
        <datafield tag="022" ind1="" ind2="">
            <subfield code="a">1538-4101</subfield>
        </datafield>
        <datafield tag="100" ind1="" ind2="">
            <subfield code="a">Adelene Y. Tan and James L. Manley</subfield>
        </datafield>
        
        <datafield tag="210" ind1="" ind2="">
            <subfield code="a">cc</subfield>
        </datafield>
        
        <datafield tag="245" ind1="" ind2="">
            <subfield code="a">TLS/FUS: A protein in cancer and ALS</subfield> 
        </datafield>
        
        <datafield tag="260" ind1="3" ind2="">
            <subfield code="b">Landes Bioscience</subfield>
            <subfield code="c">2012-09-15</subfield>
        </datafield>
        
        <datafield tag="302" ind1="" ind2="">
            <subfield code="a">3349 - 3350</subfield>
        </datafield>
        
        <datafield tag="440" ind1="" ind2="">
            
            <subfield code="a">Cell Cycle</subfield>
            <subfield code="v">11-18</subfield>
        </datafield>
        <datafield tag="449" ind1="" ind2="">
            <subfield code="o">Landes Bioscience</subfield>
        </datafield>
        <datafield tag="520" ind1="3" ind2="">
            <subfield code="a">Comment on: Tan AY, et al. Proc Natl Acad Sci USA 2012; 109:6030-5.</subfield>
        </datafield>
        <datafield tag="856" ind1="4" ind2="">
            
            <subfield code="u">http://dx.doi.org/10.4161/cc.21875</subfield>
            <subfield code="u">http://www.landesbioscience.com/journals/cc/article/21875/</subfield>
        </datafield>
 
        <datafield tag="949" ind1="" ind2="">
            <subfield code="t">article</subfield>
            <subfield code="n">Editorials: Cell Cycle Features</subfield>
        </datafield>
    </mx:record>
    <mx:record id="21842">
        <mx:leader/>
        <datafield tag="022" ind1="" ind2="">
            <subfield code="a">1538-4101</subfield>
        </datafield>
        <datafield tag="100" ind1="" ind2="">
            <subfield code="a">Fubin Li and Jeffrey V. Ravetch</subfield>
        </datafield>
        
        <datafield tag="210" ind1="" ind2="">
            <subfield code="a">cc</subfield>
        </datafield>
        
        <datafield tag="245" ind1="" ind2="">
            <subfield code="a">A general requirement for FcγRIIB co-engagement of agonistic anti-TNFR antibodies</subfield> 
        </datafield>
        
        <datafield tag="260" ind1="3" ind2="">
            <subfield code="b">Landes Bioscience</subfield>
            <subfield code="c">2012-09-15</subfield>
        </datafield>
        
        <datafield tag="302" ind1="" ind2="">
            <subfield code="a">3343 - 3344</subfield>
        </datafield>
        
        <datafield tag="440" ind1="" ind2="">
            
            <subfield code="a">Cell Cycle</subfield>
            <subfield code="v">11-18</subfield>
        </datafield>
        <datafield tag="449" ind1="" ind2="">
            <subfield code="o">Landes Bioscience</subfield>
        </datafield>
        <datafield tag="520" ind1="3" ind2="">
            <subfield code="a">Comment on: Li F, et al. Proc Natl Acad Sci USA 2012; 109:10966-71.</subfield>
        </datafield>
        <datafield tag="856" ind1="4" ind2="">
            
            <subfield code="u">http://dx.doi.org/10.4161/cc.21842</subfield>
            <subfield code="u">http://www.landesbioscience.com/journals/cc/article/21842/</subfield>
        </datafield>
 
        <datafield tag="949" ind1="" ind2="">
            <subfield code="t">article</subfield>
            <subfield code="n">Editorials: Cell Cycle Features</subfield>
        </datafield>
    </mx:record>
    <mx:record id="21843">
        <mx:leader/>
        <datafield tag="022" ind1="" ind2="">
            <subfield code="a">1538-4101</subfield>
        </datafield>
        <datafield tag="100" ind1="" ind2="">
            <subfield code="a">Alexander C. Drohat</subfield>
            <subfield code="a">Edwin Pozharski and Atanu Maiti</subfield>
        </datafield>
        
        <datafield tag="210" ind1="" ind2="">
            <subfield code="a">cc</subfield>
        </datafield>
        
        <datafield tag="245" ind1="" ind2="">
            <subfield code="a">How a mismatch repair enzyme balances the needs for efficient lesion processing and minimal action on undamaged DNA</subfield> 
        </datafield>
        
        <datafield tag="260" ind1="3" ind2="">
            <subfield code="b">Landes Bioscience</subfield>
            <subfield code="c">2012-09-15</subfield>
        </datafield>
        
        <datafield tag="302" ind1="" ind2="">
            <subfield code="a">3345 - 3346</subfield>
        </datafield>
        
        <datafield tag="440" ind1="" ind2="">
            
            <subfield code="a">Cell Cycle</subfield>
            <subfield code="v">11-18</subfield>
        </datafield>
        <datafield tag="449" ind1="" ind2="">
            <subfield code="o">Landes Bioscience</subfield>
        </datafield>
        <datafield tag="520" ind1="3" ind2="">
            <subfield code="a">Comment on: Maiti A, et al. Proc Natl Acad Sci USA 2012; 109:8091-6.</subfield>
        </datafield>
        <datafield tag="856" ind1="4" ind2="">
            
            <subfield code="u">http://dx.doi.org/10.4161/cc.21843</subfield>
            <subfield code="u">http://www.landesbioscience.com/journals/cc/article/21843/</subfield>
        </datafield>
 
        <datafield tag="949" ind1="" ind2="">
            <subfield code="t">article</subfield>
            <subfield code="n">Editorials: Cell Cycle Features</subfield>
        </datafield>
    </mx:record>
    <mx:record id="21844">
        <mx:leader/>
        <datafield tag="022" ind1="" ind2="">
            <subfield code="a">1538-4101</subfield>
        </datafield>
        <datafield tag="100" ind1="" ind2="">
            <subfield code="a">Alexander Lorenz and Matthew C. Whitby</subfield>
        </datafield>
        
        <datafield tag="210" ind1="" ind2="">
            <subfield code="a">cc</subfield>
        </datafield>
        
        <datafield tag="245" ind1="" ind2="">
            <subfield code="a">How not to get cross(ed): A novel role for FANCM orthologs in meiotic recombination</subfield> 
        </datafield>
        
        <datafield tag="260" ind1="3" ind2="">
            <subfield code="b">Landes Bioscience</subfield>
            <subfield code="c">2012-09-15</subfield>
        </datafield>
        
        <datafield tag="302" ind1="" ind2="">
            <subfield code="a">3347 - 3348</subfield>
        </datafield>
        
        <datafield tag="440" ind1="" ind2="">
            
            <subfield code="a">Cell Cycle</subfield>
            <subfield code="v">11-18</subfield>
        </datafield>
        <datafield tag="449" ind1="" ind2="">
            <subfield code="o">Landes Bioscience</subfield>
        </datafield>
        <datafield tag="520" ind1="3" ind2="">
            <subfield code="a">Comment on: Lorenz A, et al. Science 2012; 336:1585-8.</subfield>
        </datafield>
        <datafield tag="856" ind1="4" ind2="">
            
            <subfield code="u">http://dx.doi.org/10.4161/cc.21844</subfield>
            <subfield code="u">http://www.landesbioscience.com/journals/cc/article/21844/</subfield>
        </datafield>
 
        <datafield tag="949" ind1="" ind2="">
            <subfield code="t">article</subfield>
            <subfield code="n">Editorials: Cell Cycle Features</subfield>
        </datafield>
    </mx:record>
    <mx:record id="21849">
        <mx:leader/>
        <datafield tag="022" ind1="" ind2="">
            <subfield code="a">1538-4101</subfield>
        </datafield>
        <datafield tag="100" ind1="" ind2="">
            <subfield code="a">Lindsey D. Mayo</subfield>
        </datafield>
        
        <datafield tag="210" ind1="" ind2="">
            <subfield code="a">cc</subfield>
        </datafield>
        
        <datafield tag="245" ind1="" ind2="">
            <subfield code="a">Directing p53 to induce autophagy</subfield> 
        </datafield>
        
        <datafield tag="260" ind1="3" ind2="">
            <subfield code="b">Landes Bioscience</subfield>
            <subfield code="c">2012-09-15</subfield>
        </datafield>
        
        <datafield tag="302" ind1="" ind2="">
            <subfield code="a">3354 - 3354</subfield>
        </datafield>
        
        <datafield tag="440" ind1="" ind2="">
            
            <subfield code="a">Cell Cycle</subfield>
            <subfield code="v">11-18</subfield>
        </datafield>
        <datafield tag="449" ind1="" ind2="">
            <subfield code="o">Landes Bioscience</subfield>
        </datafield>
        <datafield tag="520" ind1="3" ind2="">
            <subfield code="a">Comment on: Naidu SR, et al. Cell Cycle 2012; 11:2717-28.</subfield>
        </datafield>
        <datafield tag="856" ind1="4" ind2="">
            
            <subfield code="u">http://dx.doi.org/10.4161/cc.21849</subfield>
            <subfield code="u">http://www.landesbioscience.com/journals/cc/article/21849/</subfield>
        </datafield>
 
        <datafield tag="949" ind1="" ind2="">
            <subfield code="t">article</subfield>
            <subfield code="n">Cell Cycle News &amp; Views</subfield>
        </datafield>
    </mx:record>
    <mx:record id="21850">
        <mx:leader/>
        <datafield tag="022" ind1="" ind2="">
            <subfield code="a">1538-4101</subfield>
        </datafield>
        <datafield tag="100" ind1="" ind2="">
            <subfield code="a">Joshua M. Nicholson and Daniela Cimini</subfield>
        </datafield>
        
        <datafield tag="210" ind1="" ind2="">
            <subfield code="a">cc</subfield>
        </datafield>
        
        <datafield tag="245" ind1="" ind2="">
            <subfield code="a">Doubling the deck: Tetraploidy induces chromosome shuffling and cancer</subfield> 
        </datafield>
        
        <datafield tag="260" ind1="3" ind2="">
            <subfield code="b">Landes Bioscience</subfield>
            <subfield code="c">2012-09-15</subfield>
        </datafield>
        
        <datafield tag="302" ind1="" ind2="">
            <subfield code="a">3355 - 3355</subfield>
        </datafield>
        
        <datafield tag="440" ind1="" ind2="">
            
            <subfield code="a">Cell Cycle</subfield>
            <subfield code="v">11-18</subfield>
        </datafield>
        <datafield tag="449" ind1="" ind2="">
            <subfield code="o">Landes Bioscience</subfield>
        </datafield>
        <datafield tag="520" ind1="3" ind2="">
            <subfield code="a">Comment on: Lv L, et al. Cell Cycle 2012; 11:2864-75.</subfield>
        </datafield>
        <datafield tag="856" ind1="4" ind2="">
            
            <subfield code="u">http://dx.doi.org/10.4161/cc.21850</subfield>
            <subfield code="u">http://www.landesbioscience.com/journals/cc/article/21850/</subfield>
        </datafield>
 
        <datafield tag="949" ind1="" ind2="">
            <subfield code="t">article</subfield>
            <subfield code="n">Cell Cycle News &amp; Views</subfield>
        </datafield>
    </mx:record>
    <mx:record id="21851">
        <mx:leader/>
        <datafield tag="022" ind1="" ind2="">
            <subfield code="a">1538-4101</subfield>
        </datafield>
        <datafield tag="100" ind1="" ind2="">
            <subfield code="a">Silvia Polakova</subfield>
            <subfield code="a">Miroslava Pozgajova and Juraj Gregan</subfield>
        </datafield>
        
        <datafield tag="210" ind1="" ind2="">
            <subfield code="a">cc</subfield>
        </datafield>
        
        <datafield tag="245" ind1="" ind2="">
            <subfield code="a">New evidence that SAC can tolerate misaligned chromosomes in mouse oocytes</subfield> 
        </datafield>
        
        <datafield tag="260" ind1="3" ind2="">
            <subfield code="b">Landes Bioscience</subfield>
            <subfield code="c">2012-09-15</subfield>
        </datafield>
        
        <datafield tag="302" ind1="" ind2="">
            <subfield code="a">3357 - 3357</subfield>
        </datafield>
        
        <datafield tag="440" ind1="" ind2="">
            
            <subfield code="a">Cell Cycle</subfield>
            <subfield code="v">11-18</subfield>
        </datafield>
        <datafield tag="449" ind1="" ind2="">
            <subfield code="o">Landes Bioscience</subfield>
        </datafield>
        <datafield tag="520" ind1="3" ind2="">
            <subfield code="a">Comment on: Sebestova J, et al. Cell Cycle 2012; 11:3011-8.</subfield>
        </datafield>
        <datafield tag="856" ind1="4" ind2="">
            
            <subfield code="u">http://dx.doi.org/10.4161/cc.21851</subfield>
            <subfield code="u">http://www.landesbioscience.com/journals/cc/article/21851/</subfield>
        </datafield>
 
        <datafield tag="949" ind1="" ind2="">
            <subfield code="t">article</subfield>
            <subfield code="n">Cell Cycle News &amp; Views</subfield>
        </datafield>
    </mx:record>
    <mx:record id="21852">
        <mx:leader/>
        <datafield tag="022" ind1="" ind2="">
            <subfield code="a">1538-4101</subfield>
        </datafield>
        <datafield tag="100" ind1="" ind2="">
            <subfield code="a">Chengfu Yuan</subfield>
            <subfield code="a">Ningzhi Xu and Joshua Liao</subfield>
        </datafield>
        
        <datafield tag="210" ind1="" ind2="">
            <subfield code="a">cc</subfield>
        </datafield>
        
        <datafield tag="245" ind1="" ind2="">
            <subfield code="a">Switch of FANCL, a key FA-BRCA component, between tumor suppressor and promoter by alternative splicing</subfield> 
        </datafield>
        
        <datafield tag="260" ind1="3" ind2="">
            <subfield code="b">Landes Bioscience</subfield>
            <subfield code="c">2012-09-15</subfield>
        </datafield>
        
        <datafield tag="302" ind1="" ind2="">
            <subfield code="a">3356 - 3356</subfield>
        </datafield>
        
        <datafield tag="440" ind1="" ind2="">
            
            <subfield code="a">Cell Cycle</subfield>
            <subfield code="v">11-18</subfield>
        </datafield>
        <datafield tag="449" ind1="" ind2="">
            <subfield code="o">Landes Bioscience</subfield>
        </datafield>
        <datafield tag="520" ind1="3" ind2="">
            <subfield code="a">Comment on: Panneerselvam J, et al. Cell Cycle 2012; 11:2947-55.</subfield>
        </datafield>
        <datafield tag="856" ind1="4" ind2="">
            
            <subfield code="u">http://dx.doi.org/10.4161/cc.21852</subfield>
            <subfield code="u">http://www.landesbioscience.com/journals/cc/article/21852/</subfield>
        </datafield>
 
        <datafield tag="949" ind1="" ind2="">
            <subfield code="t">article</subfield>
            <subfield code="n">Cell Cycle News &amp; Views</subfield>
        </datafield>
    </mx:record>
    <mx:record id="21876">
        <mx:leader/>
        <datafield tag="022" ind1="" ind2="">
            <subfield code="a">1538-4101</subfield>
        </datafield>
        <datafield tag="100" ind1="" ind2="">
            <subfield code="a">Ulf H. Beier</subfield>
            <subfield code="a">Liqing Wang and Wayne W. Hancock</subfield>
        </datafield>
        
        <datafield tag="210" ind1="" ind2="">
            <subfield code="a">cc</subfield>
        </datafield>
        
        <datafield tag="245" ind1="" ind2="">
            <subfield code="a">Combination of isoform-selective histone/protein deacetylase inhibitors improves Foxp3+ T-regulatory cell function</subfield> 
        </datafield>
        
        <datafield tag="260" ind1="3" ind2="">
            <subfield code="b">Landes Bioscience</subfield>
            <subfield code="c">2012-09-15</subfield>
        </datafield>
        
        <datafield tag="302" ind1="" ind2="">
            <subfield code="a">3351 - 3352</subfield>
        </datafield>
        
        <datafield tag="440" ind1="" ind2="">
            
            <subfield code="a">Cell Cycle</subfield>
            <subfield code="v">11-18</subfield>
        </datafield>
        <datafield tag="449" ind1="" ind2="">
            <subfield code="o">Landes Bioscience</subfield>
        </datafield>
        <datafield tag="520" ind1="3" ind2="">
            <subfield code="a">Comment on: Beier UH, et al. Sci Signal 2012; 5:ra45.</subfield>
        </datafield>
        <datafield tag="856" ind1="4" ind2="">
            
            <subfield code="u">http://dx.doi.org/10.4161/cc.21876</subfield>
            <subfield code="u">http://www.landesbioscience.com/journals/cc/article/21876/</subfield>
        </datafield>
 
        <datafield tag="949" ind1="" ind2="">
            <subfield code="t">article</subfield>
            <subfield code="n">Editorials: Cell Cycle Features</subfield>
        </datafield>
    </mx:record>
    <mx:record id="22096">
        <mx:leader/>
        <datafield tag="022" ind1="" ind2="">
            <subfield code="a">1538-4101</subfield>
        </datafield>
        <datafield tag="100" ind1="" ind2="">
            <subfield code="a">Olga A. Issaenko and Alexander Yu Amerik</subfield>
        </datafield>
        
        <datafield tag="210" ind1="" ind2="">
            <subfield code="a">cc</subfield>
        </datafield>
        
        <datafield tag="245" ind1="" ind2="">
            <subfield code="a">Erratum to Issaenko OA, et al. Cell Cycle Volume 11, Issue 9; pp. 1804-17</subfield> 
        </datafield>
        
        <datafield tag="260" ind1="3" ind2="">
            <subfield code="b">Landes Bioscience</subfield>
            <subfield code="c">2012-09-15</subfield>
        </datafield>
        
        <datafield tag="302" ind1="" ind2="">
            <subfield code="a">3518 - 3518</subfield>
        </datafield>
        
        <datafield tag="440" ind1="" ind2="">
            
            <subfield code="a">Cell Cycle</subfield>
            <subfield code="v">11-18</subfield>
        </datafield>
        <datafield tag="449" ind1="" ind2="">
            <subfield code="o">Landes Bioscience</subfield>
        </datafield>
        <datafield tag="856" ind1="4" ind2="">
            
            <subfield code="u">http://dx.doi.org/10.4161/cc.22096</subfield>
            <subfield code="u">http://www.landesbioscience.com/journals/cc/article/22096/</subfield>
        </datafield>
 
        <datafield tag="949" ind1="" ind2="">
            <subfield code="t">article</subfield>
            <subfield code="n">Erratum</subfield>
        </datafield>
    </mx:record>

</mx:collection>